Step 1 topics → Neurology and Special Senses → Antiepileptic Drugs (AEDs)

Antiepileptic Drugs (AEDs)

USMLE Step 1 trap: Incorrectly applies phenytoin to absence seizures instead of ethosuximide. Phenytoin is contraindicated in absence seizures and may worsen them; ethosuximide is first-line for absence seizures.

Antiepileptic drugs are a perennial high-yield topic on USMLE Step 1 because they require you to integrate three things simultaneously: seizure classification, drug mechanism, and toxicity profile. The exam will give you a clinical vignette — a child staring blankly in class, a pregnant woman with a new seizure, a patient who develops gingival overgrowth — and expect you to work backward and forward from those details to identify the drug, justify its use, or recognize its harm. You cannot memorize AEDs as a flat list; you have to know why each drug works for specific seizure types, because the mechanisms directly explain the clinical indications.

The single biggest trap on USMLE Step 1 is phenytoin and absence seizures. Students who memorize 'phenytoin = seizures' will reach for it in absence seizure questions and get it wrong — phenytoin can actually worsen absence seizures. Ethosuximide is first-line for pure absence, and valproate covers absence plus generalized tonic-clonic. A second common error is oversimplifying valproate's mechanism to 'sodium channel blocker,' which misses its T-type calcium channel blockade and GABA transaminase inhibition — the properties that make it uniquely broad-spectrum. If you only know one mechanism for valproate, you'll miss questions that hinge on why it works for absence when phenytoin doesn't.

The toxicity questions are often the most specific. Phenytoin has a distinctive toxicity fingerprint: gingival hyperplasia, hirsutism, cerebellar ataxia (nystagmus, diplopia), fetal hydantoin syndrome, and zero-order kinetics that make it easy to overdose. Carbamazepine causes agranulocytosis and aplastic anemia in addition to Stevens-Johnson syndrome — and SJS risk is dramatically elevated in patients with HLA-B*1502 (Southeast Asian ancestry), which is a testable pharmacogenomics point. Know these cold before test day.

From real student decks
95%have cards covering this topic
76%have mature cards
2median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Phenytoin is an appropriate first-line treatment for absence seizures.
Right: Phenytoin is contraindicated in absence seizures and may worsen them; ethosuximide is first-line for absence seizures.
Phenytoin blocks voltage-gated sodium channels, which is useful for the sustained repetitive firing seen in focal and tonic-clonic seizures — but absence seizures are driven by rhythmic T-type calcium channel activity in thalamocortical circuits, not by sodium channel dysfunction. Phenytoin has no effect on T-type calcium channels and can paradoxically increase absence episodes. The correct first-line agent is ethosuximide, which directly targets T-type calcium channels in thalamic neurons.
Common mistake
Wrong: Valproate works solely by blocking sodium channels like phenytoin.
Right: Valproate has multiple mechanisms: Na+ channel blockade, increased GABA (via GABA transaminase inhibition), and T-type Ca2+ channel blockade, making it broad-spectrum.
Calling valproate 'a sodium channel blocker' is like calling a Swiss Army knife 'a knife' — technically partially true but dangerously incomplete. Valproate also inhibits GABA transaminase (increasing synaptic GABA levels) and blocks T-type calcium channels, which is why it works for absence seizures when phenytoin does not. This multi-mechanism profile is precisely what makes valproate one of the few broad-spectrum AEDs effective across generalized tonic-clonic, absence, and myoclonic seizure types.
Common mistake
Wrong: Carbamazepine's most dangerous adverse effect is Stevens-Johnson syndrome in all populations.
Right: Carbamazepine causes agranulocytosis and aplastic anemia as serious hematologic toxicities, and SJS risk is markedly elevated in patients with HLA-B*1502 (Southeast Asian ancestry).
Stevens-Johnson syndrome is not the only dangerous carbamazepine toxicity — the drug also causes agranulocytosis and aplastic anemia, which require CBC monitoring and are distinct from the dermatologic risk. SJS from carbamazepine is a pharmacogenomic issue: the HLA-B*1502 allele, present at high frequency in Southeast Asian populations, dramatically increases risk and is a reason the FDA recommends genetic screening before starting carbamazepine in patients of that ancestry. Knowing both the hematologic toxicities and the HLA-B*1502 association is what separates a complete answer from a partial one.
Common mistake
Wrong: Ethosuximide blocks sodium channels like most other AEDs.
Right: Ethosuximide blocks T-type calcium channels in thalamic neurons, which is the mechanism underlying its specific efficacy in absence seizures.
Ethosuximide's mechanism is not sodium channel blockade — it specifically and selectively inhibits T-type (low-voltage-activated) calcium channels in thalamic relay neurons. This is clinically critical because the 3 Hz spike-and-wave discharge of absence seizures is generated by rhythmic thalamocortical T-type calcium channel activation; blocking these channels interrupts that circuit. No other mechanism explains why ethosuximide is exquisitely effective for absence but has no role in focal or tonic-clonic seizures.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a seizure type (absence, focal, generalized tonic-clonic, myoclonic), identify the appropriate first-line AED and explain why other AEDs are inappropriate or contraindicated for that seizure type.
  2. For each major AED (phenytoin, carbamazepine, valproate, ethosuximide, lamotrigine, levetiracetam, topiramate, phenobarbital, benzodiazepines, gabapentin), identify the specific molecular target (Na+ channel, T-type Ca2+ channel, GABA system, SV2A) that explains its clinical use.
  3. Recognize a clinical scenario describing a characteristic AED adverse effect — such as gingival hyperplasia, agranulocytosis, teratogenicity (neural tube defects, fetal hydantoin syndrome), metabolic acidosis, or Stevens-Johnson syndrome — and identify the responsible drug, including pharmacogenomic risk factors like HLA-B*1502 for carbamazepine.

Can you avoid these mistakes?

A 7-year-old girl has episodes of staring and lip-smacking lasting 10 seconds, occurring 20 times per day, with EEG showing 3 Hz spike-and-wave discharges. Her pediatrician starts phenytoin. What is wrong with this choice, and what drug should be used instead?
A patient with generalized tonic-clonic and absence seizures needs a single agent. Which AED covers both seizure types, and what are its three distinct molecular mechanisms that make this possible?
A Southeast Asian patient started on carbamazepine 3 weeks ago presents with fever, painful oral ulcers, and diffuse skin blistering. What adverse effect is this, what genetic factor predisposed this patient, and what other serious non-dermatologic toxicity should carbamazepine-treated patients be monitored for?
Rank these three AEDs by number of molecular targets: phenytoin, ethosuximide, valproate. For each, name the target(s). Which one's mechanism directly explains why it cannot treat absence seizures?

Related topics

Seizure Classification and Epilepsy Syndromes Neural Tube Formation and Derivatives Neural Crest Derivatives Neural Tube Defects Other Developmental Malformations

See how your Anki deck covers this topic.

Upload your deck for a free audit →